Preimplantation genetic testing for aneuploidy in patients of different age: a systematic review and meta-analysis

Abstract

This study aimed to summarize the current knowledge on the benefits of in vitro fertilization/intracytoplasmic sperm injection with preimplantation genetic testing for aneuploidy (PGT-A) and to discuss the role of PGT-A in patients of different ages undergoing assisted reproduction. A systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 checklist. Registration number: CRD42022354697. Studies were identified by searching the PubMed, Cochrane Library, Google Scholar, Scopus, Embase, and ClinicalTrials databases. Seven meta-analyses were performed with additional stratification of age and prognosis of the women studied. Clinical pregnancy rate per embryo transfer in patients aged >35 years was higher in the PGT-A group (<i>P</i>=0.0002) than in controls. Live birth rate (LBR) per embryo transfer in women 35 years old or younger (<i>P</i>=0.002) was higher in the PGT-A group. The LBR per patient in women aged >35 years was higher in the PGT-A group (<i>P</i>=0.004). The effects of PGT-A on LBR in patients with poor prognosis showed a statistically significant increase (<i>P</i>=0.003). There was no significant difference in the rate between the two groups. PGT-A is effective and can be recommended for patients aged >35 years undergoing assisted reproduction to improve their reproductive outcomes. Moreover, our study showed the possible benefits of PGT-A in patients with a poor prognosis. Overall, our findings suggest that PGT-A is a valuable tool for improving the reproductive outcomes of assisted reproductive procedures in older women and those with a history of pregnancy complications.